Improving Outcomes in Alzheimer’s Disease and Dementia: Emerging Treatment Advances and Recommendations

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2021 to March 1, 2022

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Biogen

Description:
Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Although not all memory loss indicates Alzheimer’s disease, one in ten people over 65 years of age, and over half of those over 85 have Alzheimer’s disease. Currently, 26 million people worldwide have this dementia. By the year 2050, over 15 million Americans may be affected with the disease. Alzheimer’s disease care costs $172 billion annually in the United States alone. However, advances in the science underlying Alzheimer’s are emerging at a rapid rate with a large number of potential agents undergoing clinical trials.

Diagnosing Alzheimer's requires careful medical evaluation, including medical history, mental status testing, physical and neurological exam, blood tests and brain imaging. As the use of biomarkers continues to grow, the potential for catching Alzheimer’s disease even earlier is crucial to improving outcomes. While there is no cure for Alzheimer’s disease or a way to stop or slow its progression, there are pharmacologic and non-pharmacologic options that may help treat symptoms. Understanding available options can help individuals living with the disease and their caregivers to cope with symptoms and improve a patient’s quality of life. There is one emerging treatment that has shown high-dose, long-duration exposure can modify the disease process and provide clinical benefit to patients with Alzheimer’s. The research has now been developed to a point where scientists can look beyond treating symptoms to think about addressing underlying disease processes.

Upon completion of this activity, participants will be able to:

• Discuss the clinical advances and guidelines for diagnosis of dementia, including screening methods and key assessments

• Assess clinical outcome measures and diagnostic testing strategies in the evaluation of Alzheimer's disease and related dementias

• Evaluate the safety and efficacy data of pharmacologic treatments to guide management decisions

• Explore the role of investigational human monoclonal antibodies for the treatment of Alzheimer’s disease

• Analyze emerging treatment strategies in patients with Alzheimer’s disease

• Examine the important roles of caregivers in managing dementia and the interventions for supporting caregivers
  
   

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)^TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Biogen

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue